In certain solid tumors, such as non‐small cell lung cancer (NSCLC) and melanoma, the effectiveness of PD‐1/PD‐L1 blockade can be tentatively predicted by assessing PD‐L1 expression [17], microsatellite stability [18], and tumor mutational burden [19] in tumor tissues. The gene discussed is CD274; the disease is non-small cell lung carcinoma.